Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use;Neuroimagen funcional en el diagnóstico de pacientes con síndrome parkinsoniano: Actualización y recomendaciones para el uso clínico

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 33, Issue 4, 2014, Pages 215-226

  Arbizu, J ^a   Luquin, M R ^a   Abella, J ^b   de la Fuente Fernandez R ^b   Fernandez Torron R ^c   Garcia Solis D ^d   Garrastachu, P ^e   Jimenez Hoyuela J M ^f   Llaneza, M ^b   Lomena F ^g   Lorenzo Bosquet, C ^h   Marti M J ^g   Martinez Castrillo, J C ⁱ   Mir, P ^d   Mitjavila, M ^j   Ruiz Martinez J ^k   Vela, L ^l  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universidad de La Coruña   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL SAN PEDRO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

more..

Author keywords

Differential diagnosis; Parkinson disease; Parkinsonism; PET; Scintigraphy; SPECT

Indexed keywords

TRACER;

ARTICLE; BASAL GANGLION; CLINICAL PRACTICE; CORTICAL NEURONAL ACTIVITY; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC NIGROSTRIATAL PATHWAY INTEGRITY; FUNCTIONAL NEUROIMAGING; HUMAN; MYOCARDIAL SYMPATHETIC INNERVATION; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; ALGORITHM; PRACTICE GUIDELINE; SCINTISCANNING;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; FUNCTIONAL NEUROIMAGING; HUMANS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84903716371     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2014.02.001     Document Type: Article

References (54)

1. Fahn S., Jankovic J. Parkinsonism. Clinical features and differential diagnosis. Principles and Practice of Movement Disorders 2007, 79-103. Churchill Livingstone Elsevier, New York. S. Fahn, J. Jankovic (Eds.).
2. Williams D.R., Lees A.J. Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009, 8:270-279.
3. Albanese A., Altavista M.C., Rossi P. Organization of central nervous system dopaminergic pathways. J Neural Transm 1986, 22:3-17.
4. García Solís D. Imagen de neurotransmisión dopaminérgica en los síndromes parkinsonianos. Rev Esp Med Nucl 2005, 24:255-275.
5. van Laere K., Varrone A., Booij J., Vander Borght T., Nobili F., Kapucu Ö.L, et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging 2010, 37:434-442.
6. Darcourt J., Booij J., Tatsch K., Varrone A., Vander Borght T., Kapucu ÖL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010, 37:443-450.
7. Booij J., Kemp P. Dopamine transporter imaging with [123I] FP-CIT SPECT: Potential effects of drugs. Eur J Nucl Med Mol Imaging 2008, 35:424-438.
8. Magistretti P.J., Pellerin L., Rothman D.L., Shulman R.G. Energy on demand. Science 1999, 283:496-497.
9. Hasselbalch S.G., Knudsen G.M., Videbaek C., Pinborg L.H., Schmidt J.F., Holm S., et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999, 48:1915-1921.
10. Spanaki M., Siegel H., Kopylev L., Fazilat S., Dean A., Liow K., et al. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology 1999, 53:1518-1522.
11. Berding G., Odin P., Brooks D.J., Nikkhah G., Matthies C., Peschel T., et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 2001, 16:1014-1022.
12. Knickmeier M., Matheja P., Wichter T., Schäfers K.P., Kies P., Breithardt G., et al. Clinical evaluation of no-carrier-added meta-[123I] iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000, 27:302-307.
13. Flotats A., Carrió I., Agostini D., le Guludec D., Marcassa C., Schaffers M., et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM cardiovascular committee and the european council of nuclear cardiology. Eur J Nucl Med Mol Imaging 2010, 37:1802-1812.
14. Verberne H.J., Feenstra C., de Jong W.M., Somsen G.A., van Eck-Smit B.L., Sokole E.B. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: A phantom study. Eur J Nucl Med Mol Imaging 2005, 32:1100-1107.
15. 123I-MIBG imaging. Semin Nucl Med 2011, 41:374-387.
16. Shahed J., Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord 2007, 13:67-76.
17. Perlmutter J.S., Eidelberg D. To scan or not to scan DaT is the question. Neurology 2012, 78:688-689.
18. Bajaj N.P., de la Fuente-Fernandez R. Role of datscan and clinical diagnosis in pd. Neurology 2012, 78:1538-1539.
19. De la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012, 78:696-701.
20. Marek K., Jennings D., Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005, 64:A274.
21. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
22. Brooks D.J., Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009, 24:949-964.
23. Gilman S., Wenning G., Low P., Brooks D., Mathias C., Trojanowski J., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
24. Tang C.C., Poston K.L., Eckert T., Feigin A., Frucht S., Gudesblatt M., et al. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 2010, 9:149-158.
25. Eckert T., Barnes A., Dhawan V., Frucht S., Gordon M.F., Feigin A.S., et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005, 26:912-921.
26. 123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012, 79:1314-1322.
27. Juh R., Pae C., Kim T., Lee C., Choe B., Suh T. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005, 383:22-27.
28. Teune L.K., Bartels A.L., de Jong B.M., Willemsen A., Eshuis S.A., de Vries J.J., et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010, 25:2395-2404.
29. Kägi G., Bhatia K.P., Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010, 81:5-12.
30. Klaffke S., Kuhn A.A., Plotkin M., Amthauer H., Harnack D., Felix R., et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord. 2006, 21:1724-1727.
31. Rascol O., Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009, 24:S732-S741.
32. Sawada H., Oeda T., Yamamoto K., Kitagawa N., Mizuta E., Hosokawa R., et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009, 16:174-182.
33. Spiegel J., Möllers M., Jost W.H., Fuss G., Samnick S., Dillmann U., et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005, 20:552-561.
34. Nagayama H., Ueda M., Yamazaki M., Nishiyama Y., Hamamoto M., Katayama Y. Abnormal cardiac [123I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010, 25:1744-1747.
35. Yoshita M., Taki J., Yokoyama K., Noguchi-Shinohara M., Matsumoto Y., Nakajima K., et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006, 66:1850-1854.
36. Hirose G. Drug induced parkinsonism. J Neurol 2006, 253:22-24.
37. Diaz-Corrales F.J., Sanz-Viedma S., Garcia-Solis D., Escobar-Delgado T., Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010, 37:556-564.
38. Zijlmans J., Evans A., Fontes F., Katzenschlager R., Gacinovic S., Lees A.J., et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord 2007, 22:1278-1285.
39. Gerschlager W., Bencsits G., Pirker W., Bloem B.R., Asenbaum S., Prayer D., et al. [123I] β-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002, 17:518-523.
40. Benítez-Rivero S., Marín-Oyaga V.A., García-Solís D., Huertas-Fernández I., García-Gómez F.J., Jesús S., et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 2013, 84:122-129.
41. Paisàn-Ruìz C., Sàenz A., de Munain A.L., Martì I., Martìnez Gil A., Martì-Massò J.F., et al. Familial Parkinson's disease: Clinical and genetic analysis of four basque families. Ann Neurol 2005, 57:365-372.
42. Adams J.R., van Netten H., Schulzer M., Mak E., Mckenzie J., Strongosky A., et al. PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
43. Hernandez D.G., Paisán-Ruíz C., McInerney-Leo A., Jain S., Meyer-Lindenberg A., Evans E.W., et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005, 57:453-456.
44. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., et al. Progression of dopaminergic dysfunction in a LRRK2 kindred A multitracer PET study. Neurology 2008, 71:1790-1795.
45. Sossi V., de la Fuente-Fernández R., Nandhagopal R., Schulzer M., McKenzie J., Ruth T.J., et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010, 25:2717-2723.
46. Ruiz-Martínez J., Gorostidi A., Goyenechea E., Alzualde A., Poza J.J., Rodríguez F., et al. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord 2011, 26:2026-2031.
47. Quattrone A., Bagnato A., Annesi G., Novellino F., Morgante L., Savettieri G., et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov Disord 2008, 23:21-27.
48. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
49. Biju G., de la Fuente-Fernández R. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Relat Disord 2009, 15:S38-S40.
50. Lee C.S., Schulzer M., de la Fuente-Fernández R., Mak E., Kuramoto L., Sossi V., et al. Lack of regional selectivity during the progression of Parkinson disease: Implications for pathogenesis. Arch Neurol 2004, 61:1920-1925.
51. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005, 62:378-382.
52. Shih M.C., de Andrade F., Augusto L., Amaro E., Felicio A.C., Ferraz H.B., et al. Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?--a [99mTc]-TRODAT-SPECT study. Mov Disord 2007, 22:863-866.
53. De la Fuente-Fernández R., Schulzer M., Kuramoto L., Cragg J., Ramachandiran N., Au W.L., et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011, 69:803-810.
54. Brooks D.J. Imaging approaches to Parkinson disease. J Nucl Med 2010, 51:596-609.